Amgen to buy Celgene’s psoriasis drug Otezla for $13.4 billion in cash

Amgen to buy Celgene’s psoriasis drug Otezla for $13.4 billion in cash

Celgene will sell its psoriasis drug Otezla for $13.4 billion in cash to Amgen, taking Celgene a step closer to a $74-billion takeover by Bristol-Myers Squibb. The deal is expected to close by 2019 end.

Tom A
Tom A
Top in Business
Get the App